{"name":"Ronaldo de Matos Esmeraldo, MD","slug":"ronaldo-de-matos-esmeraldo-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Low Tacrolimus","genericName":"Low Tacrolimus","slug":"low-tacrolimus","indication":"Organ transplant rejection prophylaxis (kidney, heart, liver)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Very Low Tacrolimus","genericName":"Very Low Tacrolimus","slug":"very-low-tacrolimus","indication":"Prevention of organ rejection in solid organ transplant recipients (kidney, heart, liver, pancreas)","status":"marketed"}]}],"pipeline":[{"name":"Low Tacrolimus","genericName":"Low Tacrolimus","slug":"low-tacrolimus","phase":"marketed","mechanism":"Low-dose tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection and inflammation.","indications":["Organ transplant rejection prophylaxis (kidney, heart, liver)","Autoimmune and inflammatory conditions (atopic dermatitis, eczema)"],"catalyst":""},{"name":"Very Low Tacrolimus","genericName":"Very Low Tacrolimus","slug":"very-low-tacrolimus","phase":"marketed","mechanism":"Very Low Tacrolimus is a reduced-dose formulation of tacrolimus that suppresses T-cell activation by inhibiting calcineurin, thereby reducing transplant rejection while minimizing immunosuppressive toxicity.","indications":["Prevention of organ rejection in solid organ transplant recipients (kidney, heart, liver, pancreas)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}